JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 164.09 $ 3.38 (2.1 %)    

Friday, 02-Aug-2024 15:59:59 EDT
QQQ $ 447.95 $ -10.91 (-2.37 %)
DIA $ 397.31 $ -6.10 (-1.51 %)
SPY $ 532.92 $ -10.11 (-1.86 %)
TLT $ 98.17 $ 2.97 (3.12 %)
GLD $ 225.36 $ -0.43 (-0.19 %)
$ 164.14
$ 164.11 x 100
$ 164.14 x 300
-- - --
$ 141.57 - $ 170.63
11,034,173
na
397.55B
$ 0.47
$ 10.46
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-25-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 02-16-2024 12-31-2023 10-K
4 10-27-2023 10-01-2023 10-Q
5 10-27-2023 10-01-2023 10-Q
6 07-31-2023 07-02-2023 10-Q
7 04-28-2023 04-02-2023 10-Q
8 02-16-2023 01-01-2023 10-K
9 10-27-2022 10-02-2022 10-Q
10 07-29-2022 07-03-2022 10-Q
11 04-29-2022 04-03-2022 10-Q
12 02-17-2022 01-02-2022 10-K
13 10-29-2021 10-03-2021 10-Q
14 07-29-2021 07-04-2021 10-Q
15 04-30-2021 04-04-2021 10-Q
16 02-22-2021 01-03-2021 10-K
17 10-23-2020 09-27-2020 10-Q
18 07-24-2020 06-28-2020 10-Q
19 04-29-2020 03-29-2020 10-Q
20 02-18-2020 12-29-2019 10-K
21 10-28-2019 09-29-2019 10-Q
22 07-29-2019 06-30-2019 10-Q
23 05-01-2019 03-31-2019 10-Q
24 02-20-2019 12-30-2018 10-K
25 10-31-2018 09-30-2018 10-Q
26 08-02-2018 07-01-2018 10-Q
27 05-01-2018 04-01-2018 10-Q
28 02-21-2018 12-31-2017 10-K
29 11-02-2017 10-01-2017 10-Q
30 08-03-2017 07-02-2017 10-Q
31 05-08-2017 04-02-2017 10-Q
32 02-27-2017 01-01-2017 10-K
33 11-04-2016 10-02-2016 10-Q
34 08-04-2016 07-03-2016 10-Q
35 05-10-2016 04-03-2016 10-Q
36 02-24-2016 01-03-2016 10-K
37 10-30-2015 09-27-2015 10-Q
38 07-31-2015 06-28-2015 10-Q
39 05-01-2015 03-29-2015 10-Q
40 02-24-2015 12-28-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-says-do-not-use-megadyne-mega-soft-pediatric-patient-return-electrodes-in-any-age-group-only-use-megadyne-mega-2000-mega-soft-patient-return-electrodes-on-patients-12-years--older

- Reuters Citing FDA 

 reported-earlier-johnson--johnsons-darzalex-faspro-quadruplet-therapy-approved-by-fda-for-initial-treatment-of-multiple-myeloma

Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of d...

 bristol-myers-johnson--johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-price-negotiations

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact fro...

 cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

 rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

 courts-congress-likely-to-stand-in-way-of-jjs-third-texas-two-step-plan-us-court-of-appeals-for-3rd-circuit-latest-to-reject-unprecedented-bankruptcy-strategy-lawyers-on-behalf-of-ovarian-cancer-victims-are-calling-on-johnson--johnson-to-end-its-war-of-attrition-against-cancer-victims

U.S. Court of Appeals for 3rd Circuit latest to reject unprecedented bankruptcy strategyLawyers on behalf of tens of thousands ...

 newly-listed-psoriasis-focused-alumis-attracts-analysts-attention-with-promising-lead-program-and-modest-valuation

Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis an...

 daiwa-capital-downgrades-johnson--johnson-to-neutral-lowers-price-target-to-150

Daiwa Capital analyst Narumi Nakagiri downgrades Johnson & Johnson (NYSE:JNJ) from Outperform to Neutral and lowers the ...

 bidens-exit-from-presidential-race-yet-another-curveball-for-equity-investors-analysts

President Biden's decision to drop out may harm healthcare and create market volatility. Kamala Harris could defend his rec...

 after-disappointing-data-johnson--johnson-halts-developing-epilepsy-drug-candidate

Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epileps...

 johnson--johnson-faces-legal-hurdle-in-talc-lawsuit-battle

Johnson & Johnson's attempt to disqualify Beasley Allen from representing plaintiffs in talc cancer cases is denied by ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION